PATI® (Protector Against Tongue Injury)
Prevention of oral trauma and airway management during seizures
ApprovedActive
Key Facts
Indication
Prevention of oral trauma and airway management during seizures
Phase
Approved
Status
Active
Company
About NeuroVice
NeuroVice is a private, commercial-stage medical device company that has developed and launched PATI®, the first FDA-cleared oral device for seizure protection. The product addresses a critical unmet need in epilepsy and seizure care by providing a safe, clinically-backed alternative to dangerous makeshift methods like spoons or towels. The company operates a direct-to-consumer and B2B model, leveraging telehealth partnerships and pharmacy distributors for prescription fulfillment. NeuroVice is positioned in the digital health and neuroscience sectors, targeting a large global patient population suffering from seizure-related oral trauma.
View full company profile